March 26
- March 26
KCAS Bio will be attending Innovation for Health in Utrecht, March 26, 2026. This events brings together key players from the Life Sciences & Health ecosystem. Centered on the theme “Bridging the Gap – From Idea to Innovation & from Patent to Patient,” the conference fosters insight sharing, collaboration, and…
April 21
- April 22
KCAS Bio will be attending German Biotech Days in Leipzig, April 21–22, 2026. German Biotech Days (DBT) bring together entrepreneurs, scientists, and key partners from across the biotech ecosystem, including investors, funding institutions, policymakers, and public administration. Supporting Biologics Drug Development KCAS Bio supports small and large molecule drug development…
March 24
- March 25
KCAS Bio will be attending NextGen Biomed 2026 in London, March 24–25, 2026. NextGen Biomed is a long-standing, community-driven platform that brings together the biologics and immunotherapy ecosystem to foster interdisciplinary collaboration and knowledge sharing across the R&D lifecycle. Supporting Biologics Drug Development KCAS Bio supports biologics drug development across…
Podcasts
In episode #97 of “The Weekly Bioanalysis” podcast, John and Dom focus on a review of 2025 drug approvals, revealing a surprisingly strong year for small molecules despite long-standing predictions of their decline. Of the 53 FDA approvals, 31 were small molecules, with additional complexity coming from ADCs and RNAi…
Blogs
Developing anti-drug antibody (ADA) assays for therapeutic peptides can be complex, particularly when the molecule is small, endogenous-like, and when no positive control exists. This article describes the stepwise development of a screening and confirmatory ADA assay for a 47-amino-acid peptide targeting a receptor involved in inflammation in a…
Podcasts
In episode 28 of “The Conversational Flow”, our hosts, Adam and Brian, discuss why standardization is essential for credible flow cytometry data at scale. They walk through the biggest sources of variability – reagents and lots, sample handling and shipping time, anticoagulants and processing choices (whole blood vs. PBMCs, fresh…
March 24
- March 25
KCAS Bio will be attending Venture Connect in Durham, North Caroline on March 24-25, 2026. This event Brings together 200+ venture firms and capital sources to hear cutting-edge innovation in multiple verticals, and build strategic relationships that drive fundraising and business development. Venture Connect is the Southeast’s premier capital and…
April 30
- April 30
This new symposium series from PBSS will provide important value to life science industry scientists, since much of the R&D work of our industry nowadays is done at the vendors (CROs, CDMOs, tool makers etc). These scientific symposia will present unique technologies and valuable scientific case studies from vendor labs. …
Blogs
Bioanalysis sits at the intersection of science, regulation, and application. As therapeutic modalities grow more complex and development timelines compress, the role of bioanalysis continues to expand beyond data generation into strategic enablement. To better understand what lies ahead, we asked a diverse group of leaders across KCAS Bio, representing…
Blogs
Why Cell Stimulation Matters in Flow Cytometry Many flow cytometry users are happy to start an experiment with a general protocol and a question about their specimen: Will my cells make more cytokines or express more markers after activation? In a healthy person, immune cells like B cells, T cells,…
News
KCAS Bio is now a Certified Service Provider (CSP) for the ArgoTM HT platform, offering NULISATM services using Alamar Biosciences technology. Our team is fully trained on the Argo™ HT platform to deliver high-quality, reliable, and highly sensitive assay results, whether using custom single-plex assays for low-abundance…
webinars
The NULISA™ / Argo™ HT platform is a new, cutting-edge technology with strong potential in ultra-sensitive biomarker detection and targeted proteomics. You can now watch KCAS Bio’s XTalks webinar to learn more about how we leverage this technology for the analysis of low-abundance biomarkers. Abstract In drug…